Share：
Share this content in WeChat
X
[Chinese][PDF]132474
• Clinical Article •
Tentative discussion on cardiac magnetic resonance in differentiating common types of cardiac amyloidosis
LIAO Xuan  ZENG Mu  ZHANG Jiamin  LIU Jun 

Cite this article as: Liao X, Zeng M Zhang JM, et al. Tentative discussion on cardiac magnetic resonance in differentiating common types of cardiac amyloidosis[J]. Chin J Magn Reson Imaging, 2021, 12(9): 30-35. DOI:10.12015/issn.1674-8034.2021.09.007.


[Abstract] Objective To investigate the role of cardiac magnetic resonance (CMR) in differentiating common types of cardiac amyloidosis (CA). Materials andMethods Retrospective analysis was performed on 57 cases of CA diagnosed by pathology and undergoing CMR examination, and they were divided into two groups: the cardiac light-chain amyloidosis group (AL-CA group) (n=37) and the transthyretin-related amyloidosis group (ATTR-CA group)(n=20). The characteristics and scope of late gadolinium enhancement (LGE), extracellular volume (ECV), left ventricular ejection fraction (LVEF), the global and the level (the base, middle, apex) 3D radial strain rate (RS), the circumferential strain rate (CS), the longitudinal strain rate (LS) parameters were collected and statistically analyzed to learn about the differences between the two groups.Results (1) The scores of right ventricular LGE (χ2=12.10, P＜0.01), atrial LGE (χ2=16.34, P＜0.01), transmural LGE (χ2=12.98, P＜0.01) and query amyloid late enhancement (QALE) (χ2=128.50, P＜0.01) in the ATTR-CA group were wider than those in the AL-CA group, the differences were statistically significant (all P＜0.05), while there was no significant difference in subendocardial LGE between the two groups (χ2=0.07, P=0.79).(2) ECV of basal segment (t=-2.51, P=0.02), middle segment (t=-2.13, P=0.04) and average ECV (t=-2.15, P=0.04) of ATTR-CA group were higher than those of AL-CA group, the differences were statistically significant (all P＜0.05), but there was no significant difference in ECV of apical segment between the two groups (t=-1.47, P=0.15). (3) The global longitudinal strain rate (GLS) (t=2.97, P＜0.01), the basal longitudinal strain rate (BLS) (t=3.43, P＜0.01), the middle longitudinal strain rate (MLS) (U=200.50, P＜0.01), and the apex longitudinal strain rate (ALS) (t=2.38, P=0.02) in the ATTR-CA group were higher than those in AL-CA group, and the differences were statistically significant (all P＜0.05). There was no statistically significant difference between the two groups in the global radial strain rate (GRS) (U=243.50, P=0.06), the basal radial strain rate (BRS) (U=315.00, P=0.53), the middle radial strain rate (MRS) (U=294.50, P=0.32), and the apex radial strain rate (ARS) (U=254.5, P=0.09). And there also was no statistically significant difference between the two groups in the global circumferential strain rate (GCS) (t=1.45, P=0.15), the basal circumferential strain rate (BCS) (t=0.52, P =0.60), the middle circumferential strain rate (MCS) (t=1.02, P=0.31), and the apex circumferential strain rate (ACS) (t=1.70, P=0.09). There was no significant statistical difference in relative apical sparing of longitudinal strain (RAS-LS) between the two groups (U=254.5, P=0.09).Conclusions CMR has certain value in CA typing. The LGE, QALE score and ECV value in the ATTR-CA group were significantly higher than those in the AL-CA group, but the local or global LS of left ventricular was lower than that in the AL-CA group.
[Keywords] cardiac magnetic resonance；cardiac amyloidosis；typing；light-chain amyloidosis；transthyretin-related amyloidosis；strain

LIAO Xuan   ZENG Mu   ZHANG Jiamin   LIU Jun*  

Department of Radiology, Second Xiangya Hospital, Central South University, Changsha 410011, China

Liu J, E-mail: junliu123@csu.edu.cn

Conflicts of interest   None.

Received  2021-05-12
Accepted  2021-07-12
DOI: 10.12015/issn.1674-8034.2021.09.007
Cite this article as: Liao X, Zeng M Zhang JM, et al. Tentative discussion on cardiac magnetic resonance in differentiating common types of cardiac amyloidosis[J]. Chin J Magn Reson Imaging, 2021, 12(9): 30-35. DOI:10.12015/issn.1674-8034.2021.09.007.

[1]
Cuddy S, Falk RH. Amyloidosis as a systemic disease in context[J]. Can J Cardiol, 2020, 36(3): 396-407. DOI: 10.1016/j.cjca.2019.12.033.
[2]
Xu J, Wang M, Shen Y, et al. Effects of amyloid light-chain amyloidosis on clinical characteristics and prognosis in multiple myeloma: a single-center retrospective study[J]. Cancer Manag Res, 2021, 13: 1343-1356. DOI: 10.2147/CMAR.S287922.
[3]
Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS)[J]. Am Heart J, 2012, 164(2): 222-228. DOI: 10.1016/j.ahj.2012.04.015.
[4]
Rubin J, Maurer MS. Cardiac amyloidosis: overlooked, underappreciated, and treatable[J]. Annu Rev Med, 2020, 71(1): 203-219. DOI: 10.1146/annurev-med-052918-020140.
[5]
Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis[J]. Clin Med (Lond), 2018, 18(Suppl 2): s30-s35. DOI: 10.7861/clinmedicine.18-2-s30.
[6]
Seetharam K, Lerakis S. Cardiac magnetic resonance imaging: the future is bright[J]. F1000Res, 2019, 8(F1000 Faculty Rev):1636. DOI: 10.12688/f1000research.19721.1.
[7]
Guo YY, Tan LH, Jiang MC, et al. Evaluation of myocardial strain differences of cardiac amyloidosis and other left ventricular hypertrophy diseases with cardiovascular magnetic resonance tissue tracking technique[J]. Chin J Med Imaging Technol, 2020, 36(3): 382-386.
[8]
Chatzantonis G, Bietenbeck M, Florian A, et al. Diagnostic value of the novel CMR parameter "myocardial transit-time" (MyoTT) for the assessment of microvascular changes in cardiac amyloidosis and hypertrophic cardiomyopathy[J]. Clin Res Cardiol, 2021, 110(1): 136-145. DOI: 10.1007/s00392-020-01661-6.
[9]
Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis[J]. JACC Cardiovasc Imaging, 2014, 7(2): 133-142. DOI: 10.1016/j.jcmg.2013.08.015.
[10]
Fontana M, Banypersad S M, Treibel T A, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study[J]. Radiology, 2015, 277(2): 388-397. DOI: 10.1148/radiol.2015141744.
[11]
Li R, Yang ZG, Xu HY, et al. Myocardial deformation in cardiac amyloid light-chain amyloidosis: assessed with 3T cardiovascular magnetic resonance feature tracking[J]. Sci Rep, 2017, 7(1): 3794. DOI: 10.1038/s41598-017-03699-5.
[12]
Guan J, Mishra S, Qiu Y, et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity[J]. EMBO Mol Med, 2014, 6(11): 1493-1507. DOI: 10.15252/emmm.201404190.
[13]
Seetharam K, Lerakis S. Cardiac magnetic resonance imaging: the future is bright[J]. F1000Res, 2019, 8(F1000 Faculty Rev):1636. DOI: 10.12688/f1000research.19721.1
[14]
Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis[J]. J Am Coll Cardiol, 2017, 70(4): 466-477. DOI: 10.1016/j.jacc.2017.05.053.
[15]
Imperlini E, Gnecchi M, Rognoni P, et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells[J]. Sci Rep, 2017, 7(1): 15661. DOI: 10.1038/s41598-017-15424-3.
[16]
Manral P, Reixach N. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage[J]. Biosci Rep, 2015, 35(1): e00172. DOI: 10.1042/BSR20140155.
[17]
Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis[J]. Circ Res, 2021, 14, 128(10): 1554-1575. DOI: 10.1161/CIRCRESAHA.121.318187.
[18]
Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types[J]. Circulation, 2009, 120(13): 1203-1212. DOI: 10.1161/CIRCULATIONAHA.108.843334.
[19]
Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?[J]. J Intern Med, 2008, 263(3): 294-301. DOI: 10.1111/j.1365-2796.2007.01888.x.
[20]
Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis[J]. Circulation, 2015, 132(16): 1570-1579. DOI: 10.1161/circulationaha.115.016567.
[21]
Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis[J]. JACC Cardiovasc Imaging, 2010, 3(2): 155-164. DOI: 10.1016/j.jcmg.2009.09.023.
[22]
Bhogal S, Ladia V, Sitwala P, et al. Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions[J]. Curr Probl Cardiol, 2018, 43(1): 10-34. DOI: 10.1016/j.cpcardiol.2017.04.003.

PREV Diagnostic performance of MRI and CT for hepatocellular carcinoma less than 3cm based on liver reporting and data system version 2018
NEXT The stronger sensitivity to missed chances in individuals with IGD: a resting-state fMRI study
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn